STLNStockStarling Oncology, Inc.
Verdicts genuinely change. Free email alert the moment STLN's does — no target price to set, unlike a price alert.
Near limit Ratio screen, 1 of 7 decided standards passing. AAOIFI, Dow Jones Islamic are within 3 points of their line. Even if they all crossed, the majority verdict would stay Not compliant. What would change it
Whether this company clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Trade setup
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
Trade plan
Posted with a stop, a target and the level that invalidates it. It resolves into the public record either way.
Why this signal?
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
Starling Oncology, Inc. (STLN) is currently considered not halal (non-compliant), per our in-house ratio engine (last assessed 2026-08-28). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
434 other Healthcare stocks pass this same screen. See compliant Healthcare stocks →
How the status reached this point
Non-compliant since Nov 20, 2026
First seen by our daily status check on Nov 20, 2026; it read Not rated on Nov 19, 2026, so the change landed between those two checks.
$3.18 — last close we recorded while it was still Not rated, Nov 19, 2026
- Nov 20, 2026 Not rated → Non-compliant1 of 7 decided standards pass; AAOIFI debt ratio 30.1%; figures as of Sep 30, 2026
- Nov 17, 2026 Tracking began Nothing before this date is on record.
Read once a day from the status this page publishes, last on Nov 21, 2026. The per-methodology record is under “What changed, and when” in the in-house research.
🕌 In-house Compliance Research
Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.
AAOIFI divides by the market cap: $324.3M as of 2026-11-20.
Business activity: cleared (no excluded categories detected)
AAOIFI Fail 2 of 3 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 30.13% | 30.00% | Fail(0.1pp over) |
| Interest-bearing investments | 11.38% | 30.00% | Pass(18.6pp buffer) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
Usmani Fail 4 of 5 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 52.07% | 33.00% | Fail(19.1pp over) |
| Interest-bearing investments | 19.65% | 33.00% | Pass(13.4pp buffer) |
| Non-liquid assets | 48.04% | at least 20.00% | Pass(28.0pp above the floor) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
| Net liquid assets per share | $-26.1M | under mkt cap $324.3M | Pass |
MSCI Fail 2 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 52.05% | 33.33% | Fail(18.7pp over) |
| Cash + interest-bearing securities | 19.65% | 33.33% | Pass(13.7pp buffer) |
| Accounts receivable | 51.96% | 33.33% | Fail(18.6pp over) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
FTSE Fail 2 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 38.62% | 33.33% | Fail(5.3pp over) |
| Cash + interest-bearing securities | 19.65% | 33.33% | Pass(13.7pp buffer) |
| Accounts receivable | 51.96% | 50.00% | Fail(2.0pp over) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
Dow Jones Islamic Market Pass 4 of 4 ratios pass
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 29.35% | 33.00% | Pass(3.7pp buffer) |
| Cash + interest-bearing securities | 11.08% | 33.00% | Pass(21.9pp buffer) |
| Accounts receivable | 18.22% | 33.00% | Pass(14.8pp buffer) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
S&P Shariah Fail 3 of 4 ratios pass
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 39.15% | 33.00% | Fail(6.1pp over) |
| Cash + interest-bearing securities | 14.78% | 49.00% | Pass(34.2pp buffer) |
| Accounts receivable | 24.30% | 49.00% | Pass(24.7pp buffer) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
MSCI M-Series Fail 3 of 4 ratios pass
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 39.15% | 33.33% | Fail(5.8pp over) |
| Cash + interest-bearing securities | 14.78% | 33.33% | Pass(18.6pp buffer) |
| Accounts receivable | 39.08% | 49.00% | Pass(9.9pp buffer) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
How close is it to flipping?
Every current reading against its own line, closest first. A verdict is only as durable as that distance.
The numbers the ratios are built from
Read from STLN's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.
| Line | Figure | As reported | Read from |
|---|---|---|---|
| RevenueTotal revenue for the period | $502.7M | 2026-09-30 | RevenueFromContractWithCustomerExcludingAssessedTax |
| Interest-bearing debtShort and long-term borrowings | $72.5M | 2026-09-30 | LongTermDebtNoncurrent |
| Cash and interest-bearing securitiesCash, equivalents and marketable securities | $36.9M | 2026-09-30 | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents |
| Total assetsBalance sheet total | $187.8M | 2026-09-30 | Assets |
| Market capDenominator for AAOIFI | $324.3M | live quote | price x shares |
| 36-month average market capDenominator for S&P Shariah and MSCI M-Series | $242.7M | 756 trading days | closes x shares |
| 24-month average market capDenominator for Dow Jones Islamic Market | $325.5M | 504 trading days | closes x shares |
| Non-permissible revenueInterest and excluded income | $0 | 2026-09-30 | no interest-income tag reported in 3+ years (treated as $0) |
Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.
Sources
Filing information. Balance sheet: Quarterly report (10-Q) filed 2026-11-06, period ended 2026-09-30. Income statement: Annual report (10-K) filed 2026-03-12, period ended 2026-09-30. Screened 2026-11-20.
-
Total assets$187.8M
Assets· period ended 2026-09-30 · 10-Q filed 2026-11-06 -
Interest-bearing debt$72.5M
LongTermDebtNoncurrent· period ended 2026-09-30 · 10-Q filed 2026-11-06 -
Cash and interest-bearing securities$36.9M
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents· period ended 2026-09-30 · 10-Q filed 2026-11-06 -
Receivables$60.7M
AccountsReceivableNetCurrent· period ended 2026-09-30 · 10-Q filed 2026-11-06 -
Revenue$502.7M
RevenueFromContractWithCustomerExcludingAssessedTax· period ended 2025-12-31 · 10-K filed 2026-03-12 -
Interest income (non-permissible)$0
no interest-income tag reported in 3+ years (treated as $0)· income statement as of 2026-09-30 · no filing link for this figure -
Market cap$324.3MMarket quote passed in by the screen (Finnhub company profile; Yahoo Finance where Finnhub has none), 2026-11-20 · not a filing figure, so no link
5 reported values cited from 2 SEC filings, read from SEC's XBRL company facts when this symbol was screened. A link opens the filing's index on EDGAR.
What changed, and when
Verdict history for STLN. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.
- 2026-11-20 Unverified → Pass filing re-screen
- 2026-11-20 Unverified → Fail filing re-screen
- 2026-11-20 Pass → Fail filing re-screen
Tracked since 2026-09-07.
What would change the status
The headline verdict is the majority of the decided ratio standards — 1 pass and 6 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2026-09-30; market cap as stored on 2026-11-20.
Within 3 points of the line
- AAOIFI debt ratio: 0.1pp over
- Dow Jones Islamic debt ratio: 3.0pp buffer
AAOIFI, Dow Jones Islamic are within 3 points of their line. Even if they all crossed, the majority verdict would stay Not compliant.
The ratios that move with the share price
AAOIFI's debt ratio is $97.7M debt (operating leases included, as the screen counts it) over a market cap of $324.3M (as of 2026-11-20), 30.1% against a 30% line.
It would pass if the market cap rose above $325.8M (+0%), about $3.19 a share against $3.18 implied by the screen's own figures.
AAOIFI would then pass; the majority verdict would stay Not compliant (2 of 7 decided standards passing).
At the screen's market cap, it would take $430,565 less debt to clear the line.
AAOIFI would then pass; the majority verdict would stay Not compliant (2 of 7 decided standards passing, counting every standard that divides the same figure).
AAOIFI's investments ratio (11.4% against a 30% line) would only fail if the market cap fell by 62%, to $123.0M.
Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.
Shariah-compliant alternatives
Compliant companies in Medical Care Facilities listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.
| Company | Market cap | Price, day |
|---|---|---|
| EHCEncompass Health Corp | $11.9B | — |
| ENSGEnsign Group Inc | $10.5B | — |
| CHEChemed Corp. | $7.1B | — |
| LFSTLifeStance Health Group Inc | $4.6B | — |
| NHCNational Healthcare Corp. | $3.6B | — |
A dash means no fresh quote is cached for that symbol; this list does not fetch one.
Funds that hold STLN
None of the 247 funds whose filed holdings we currently hold can be shown owning STLN shares. That set is a fixed list of widely held index funds and Shariah funds, plus the funds our look-through has read most recently. It is not every fund that owns STLN.
Sorted by STLN’s share of each fund, from the fund’s latest SEC N-PORT filing. “Compliant by weight” is the share of the fund’s holdings our look-through screens compliant. A fund is listed only where its filing is mostly equity and names STLN once, so a bond is not counted as the shares; 1 more fund name STLN in a way we cannot separate from its bonds, and is not listed. Shariah funds are those with a recorded certification, on our halal ETF list, or named Shariah, Islamic, Halal or Sukuk.
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Ken Griffin | Citadel Advisors | $23M | 0.0% | 2026-09-30 |
| Peter Brown | Renaissance Technologies | $7M | 0.0% | 2026-09-30 |
| Israel Englander | Millennium Management | $4M | 0.0% | 2026-09-30 |
| Steven Cohen | Point72 Asset Management | $3M | 0.0% | 2026-09-30 |
| Paul Tudor Jones | Tudor Investment Corp | $1M | 0.0% | 2026-09-30 |
| Jefferies | Jefferies Financial Group | $0M | 0.0% | 2026-09-30 |
| Joel Greenblatt | Gotham Asset Management | $0M | 0.0% | 2026-09-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 26.50 | BUY |
| Stochastic %K (14) | 0.74 | BUY |
| CCI (20) | -92.78 | NEUTRAL |
| Williams %R (14) | -99.26 | BUY |
| MACD (12,26,9) | -0.20 | SELL |
| ROC (10) | -17.13 | SELL |
| Momentum (10) | -0.62 | SELL |
| EMA (10) | 3.75 | SELL |
| SMA (10) | 3.61 | SELL |
| EMA (20) | 4.53 | SELL |
| SMA (20) | 4.93 | SELL |
| EMA (30) | 4.98 | SELL |
| SMA (30) | 5.52 | SELL |
| EMA (50) | 5.41 | SELL |
| SMA (50) | 5.93 | SELL |
| EMA (100) | 5.50 | SELL |
| SMA (100) | 5.87 | SELL |
| EMA (200) | 4.81 | SELL |
| SMA (200) | 4.80 | SELL |
About Starling Oncology, Inc.
Healthcare · Medical Care Facilities
Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The company was formerly known as The Oncology Institute, Inc. and changed its name to Starling Oncology, Inc. in August 2026. Starling Oncology, Inc. was founded in 2007 and is headquartered in Cerritos, California.
Background via Yahoo Finance — informational, not part of the verdict.
Latest Signal — 2026-11-10
Stop 2.80 Now 3.00 Target 5.97
Average — needs more confirmation before sizing up
SMC — Top Down
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 64 |
| ⏰ 4H | BEARISH | 43 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | BEARISH | 130 |
| ⏲ 5-Min | RANGING | 234 |
Momentum & Volume
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
Peer Movement
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
Before you act on this
The questions worth asking about any verdict on this page, answered plainly.
Is this a fatwa?
No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.
Why can the standards disagree?
Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.
How often is this re-screened?
Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.
Do I need to purify dividends?
If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Compare with
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider Activity (90d)
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
NO DATA 0 buys · 0 sells
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-11-17 · Asset managers net 895049 (-19081)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.